Summary
Boston Scientific Corporation (BSX) has announced a significant strategic investment in MiRus LLC, a private company focused on cardiovascular and orthopedic biomaterials and implantable solutions. On May 15, 2026, BSX acquired a 33.75% non-voting equity stake in MiRus for $1.5 billion (inclusive of a prior $100 million payment). This initial investment also grants BSX an exclusive option to acquire 100% of MiRus's TAVR System subsidiary, TAVR-Structural Heart NewCo, for an additional $3.0 billion, contingent upon the achievement of specific clinical and regulatory milestones. The TAVR System is a transcatheter aortic valve replacement device currently undergoing a randomized controlled clinical trial for FDA Premarket Approval.
Key Highlights
- 1Boston Scientific makes a $1.5 billion initial investment in MiRus LLC, acquiring a 33.75% non-voting equity stake.
- 2BSX holds an exclusive option to acquire 100% of MiRus's TAVR System subsidiary for an additional $3.0 billion.
- 3The acquisition of the TAVR System subsidiary is contingent on MiRus achieving certain clinical and regulatory milestones.
- 4MiRus is developing a transcatheter aortic valve replacement (TAVR) system with FDA Investigation Device Exemption for a pivotal clinical trial.
- 5The TAVR System subsidiary will house all tangible and intangible assets related to the TAVR System business.
- 6The agreement includes potential future payments to MiRus based on net sales of the TAVR System if the option is exercised.
- 7BSX also has an option to acquire mitral and tricuspid replacement valve assets from MiRus.
Frequently Asked Questions
The investment provides Boston Scientific with strategic access to MiRus's proprietary biomaterials and implantable solutions, particularly its TAVR System, which targets the cardiovascular disease market. This move aims to enhance BSX's portfolio in structural heart interventions and potentially accelerate its market presence in this high-growth area.
The initial investment is $1.5 billion, with an additional $3.0 billion payable if Boston Scientific exercises its option to acquire the TAVR System subsidiary. This brings the total potential commitment to $4.5 billion, excluding potential future royalties to MiRus based on TAVR System net sales and the separate option for mitral and tricuspid valve assets.
The additional payment of $3.0 billion is contingent upon MiRus achieving certain clinical and regulatory milestones related to its TAVR System. While the filing doesn't detail these specific milestones, they likely relate to the successful completion of clinical trials and obtaining necessary FDA approvals for the TAVR System.
If Boston Scientific does not exercise the Call Option or if the option does not close, the company's equity interest in MiRus will be forfeited or reduced by approximately 75%, or potentially exchanged for an interest in the TAVR-Structural Heart NewCo, depending on the specific circumstances outlined in the agreement.